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Aim To evaluate the effects of bosentan, sildenafil, and 
combined therapy on the cardiovascular system using im-
pedance cardiography (ICG) in rats with monocrotaline 
(MCT)-induced pulmonary arterial hypertension (PAH).
Methods Seventy male Wistar-albino rats were random-
ized into five groups. A single dose of MCT was given to all 
rats, except to the control group. After 4 weeks, bosentan, 
sildenafil, and combined treatment was started and lasted 
for 3 weeks. The last group that developed PAH did not re-
ceive any medication. Echocardiographic evaluation was 
performed to determine the PAH development. Thoracic 
fluid content index (TFCI), stroke volume index (SI), heart 
rate (HR), cardiac index (CI), and myocardial contractility in-
dex (IC) were determined. All procedures were performed 
at the baseline and after 4 and 7 weeks.
Results Echocardiographic parameters showed that the 
all MCT-injected rats developed PAH. There were no sig-
nificant inter- and intra-group differences in TFCI, SI, and 
IC (P > 0.05), but at the 7th week, CI value in the sildena-
fil-treated PAH rats was significantly higher than in other 
groups and HR of PAH rats with combined therapy was sig-
nificantly lower than in other groups.
Conclusion PAH did not have an effect on LV function of 
rats, or if it did, the effect was compensated by physiologi-
cal processes. Also, sildenafil treatment deteriorated the LV 
cardiac index.
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Pulmonary arterial hypertension (PAH) is a chronic lung 
disease characterized by increased pulmonary artery pres-
sure, pulmonary vascular damage, and medial hypertro-
phy of pulmonary arterioles, leading to right ventricular 
(RV) hypertrophy, RV failure, and eventually death (1). The 
monocrotaline (MCT)-induced model of PAH is the most 
used model in rats. MCT is a pyrrolizidine alkaloid from the 
plant Crotalaria spectabilis. A single injection of MCT results 
in injury to the vascular endothelium of the lung, pulmo-
nary hypertension, and RV hypertrophy and failure within 
3 or 4 weeks (2-5).
A key feature of PAH is deregulation of important vasodila-
tory mechanisms in the pulmonary circulation, including 
increased expression of phosphodiesterase 5 (PDE5) (6). 
Acute and chronic experimental models of PAH use PDE5 
inhibitor sildenafil to reduce pulmonary pressure (7,8). An-
other important PAH treatment method is by endothelin 
(ET) receptor antagonist bosentan (9). The endothelin sys-
tem is highly active in PAH and causes sustained vasocon-
striction of pulmonary arteries. It increases the autogenic 
activity of smooth muscle cells and fibroblasts in the pul-
monary vessel wall, thereby decreasing the lumen of pul-
monary vessels and also contributing to increased pulmo-
nary vascular resistance (10,11). It is also known that ET 
receptor expression in the RV myocardium increases due 
to PAH (12).
Heart failure due to PAH can be identified by clinical symp-
toms that are linked to hemodynamic indices of right heart 
failure (3,13). Because of the major differences between left 
and right heart hemodynamics and potentially different 
responses to pressure overload, the data obtained for RV 
myocardium do not have to be applicable to the left ven-
tricle (LV). In addition, although chronic pulmonary hyper-
tension selectively overloads the RV, there also manifests 
LV dysfunction (14). However, hemodynamic indices of the 
left heart and treatment effects on them cannot be iden-
tified in this situation. The aim of this study is to evaluate 
the effects of PAH and bosentan, sildenafil, and combined 
treatments on the LV hemodynamic parameters by imped-
ance cardiography (ICG) in rats with MCT-induced PAH.
MaTerial anD MeTHODS
animal preparation and experimental protocol
The study was conducted in the Biophysics Laboratory 
(Faculty of Medicine, Mersin University, Mersin, Turkey) be-
tween March and May in 2013. All experiments and pro-
tocols were performed according to the guidelines of the 
European Convention for the Protection of Vertebrate Ani-
mals used for Experimental and other Scientific Purposes 
(15) and approved by the Medical Faculty Experimentation 
Ethics Committee of Mersin University. Seventy male Wistar-
Albino rats (12 week old; 220-320 g) were purchased from 
Clinical and Experimental Research Laboratory of Mersin 
University. They were housed under standard conditions 
(12 h light/dark cycle, 22 ± 2°C, relative humidity 50%-70%) 
and provided access to standard rat nutrients and purified 
drinking water ad libitum. After one week of acclimatiza-
tion, rats were assigned randomly into the control group 
and four experimental groups – group treated only with 
MCT (PAH), PAH group treated with bosentan (PBOS; 300 
mg/kg/d), PAH group treated with sildenafil (PSIL; 100 mg/
kg/d), and PAH group treated with bosentan and sildena-
fil (PCOM; 300 mg/kg/d of bosentan and 100 mg/kg/d of 
sildenafil), each containing 14 animals. For induction of 
PAH, MCT dissolved in 1 N HCl (pH adjusted to 7.4 with 1 
N NaOH; Sigma-Aldrich, Interlab Corporation, Istanbul, Tur-
key) was administered as a single subcutaneous injection 
of 60 mg/kg in a volume of 3 mL/kg after baseline mea-
surement, while control rats received an equal volume of 
saline. Depending on the induction of PAH that was con-
firmed by echocardiography, treatments with PBOS, PSIL, 
or combined therapy were initiated 4 weeks after MCT in-
jections and designated doses were given daily for 3 weeks 
in a volume of 2 mL by oral gavage. Control rats were ad-
ministered the same amount of saline. No additional treat-
ments were given to PAH rats. All rats were kept alive for 7 
weeks and body weight was measured once weekly, while 
length (mouth to tail) was measured at the baseline, 4th, 
and 7th week.
indirect determination of blood pressure
Systolic (SBP) and mean arterial blood pressure (MABP) val-
ues were measured by tail-cuff method using a non-invasive 
indirect blood pressure system (MAY NIBP-200A, Commat 
Ltd Inc., Ankara, Turkey), which is compatible with BIOPAC 
MP100 Data Acquisition System (Biopac System Inc., San-
ta Barbara, CA, USA). The rats were first placed in an acrylic 
chamber (MAY Tail Heating-B, Commat Ltd Inc.) at 37°C for 
20-30 min with an acrylic restrainer and then transferred to 
a standard setup with tail cuff and infrared sensor (RXTCUF-
SENSOR11, Biopac System Inc.), which is compatible with 
NIBP-200A. The cuff with infrared sensor was placed on 
the rat’s tail immediately after heating. SBP and MABP val-
ues were recorded with BIOPAC Acknowledge Software 
(V3.5.7, Biopac System Inc.) and the average value of 
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at least five consecutive readings was obtained for each rat. 
Rats had been allowed to accustom to this procedure for 
7 days before experiments were performed. All measure-
ments were performed by the same person, who was blind-
ed to the purpose of the study. SBP and MABP measure-
ments were performed at the baseline, 4th, and 7th week.
Transthoracic echocardiography (TTe)
RV function was determined by TTE using Vivid I Cardiovas-
cular Ultrasound System (S/N: 001651, General Electric, Tirat 
Convel, Israel) equipped with a 10 MHz probe. Before pro-
cedure, rats were sedated with ketamine (100 mg/kg; ip), 
their anterior and bilateral (right and left) thoracic regions 
were shaved, and they were placed in anterior position. Ul-
trasound gel was placed on the thorax to optimize visibility. 
Pulmonary artery acceleration time (PAAT; ms) and RV sys-
tolic pressure from tricuspid valve regurgitation (TR) were 
measured (Figures 1A and B, respectively). PAAT values were 
assessed from parasternal view by pulse-wave Doppler and 
TR values were assessed from a 4-chamber apical view by 
color flow and continuous-wave Doppler at the best view 
position of the mitral and tricuspid valves. Right ventricu-
lar systolic pressure (RVSPECHO; mmHg) was calculated using 
Bernoulli’s equation (RVSPECHO = 4 × TR
2). TTE measurements 
were performed at the baseline, 4th, and 7th week and 
were completed within 5 to 10 min per rat.
impedance cardiography
ICG recordings were performed by EBI100C module in 
BIOPAC MP 100 Acquisition System (Biopac System Inc.) in 
the same way as in our previous study (16). Immediately 
after TTE measurements, rats were placed in supine posi-
tion and the left part of the neck was shaved. Four pairs 
of electrodes (Paired EL500 Electrodes, Biopac System Inc.) 
were placed on the left side of the neck and the thorax 
(Figure 2), and electrical current (70 kHz, 2.5 mA) was ap-
plied through the outer electrodes (the highest electrode 
on the neck and the lowest electrode on the thorax), while 
the inner electrodes measured the pulsatile changes in 
voltage. The voltage changes through the thorax reflect 
pulsatile alterations in thorax impedance and indicate 
stroke volume (SV; mL/beat). SV was calculated using the 
formula previously described by Sramek and Bernstein 
(17), VEPT × LVET × ((dZ/dt)max / Zo), where LVET (sec) is the 
left ventricular ejection time, dZ/dtmax (ohm/s) the maxi-
mum rate of change in impedance, and Z0 (ohm) the base 
impedance. VEPT (mL) is the volume of electrically partici-
pating tissue, and was calculated from L3/4.25 ratio, where 
L (cm) is the distance between the inner electrodes (18). 
Cardiac output (CO; L/min) is the product of heart rate (HR; 
beats/min) and SV. To record HR, three standard ECG elec-
trodes were placed in Lead I configuration (Figures 2 and 
3) and ECG signals were recorded by an ECG100C module. 
Besides ECG, heart sounds were also recorded by DA100C 
module with a physiological microphone (TSD108, Biopac 
System Inc.) (Figure 2), and the interval between the first 
(S1) and the second (S2) heart sound was represented by 
LVET (Figure 3). Body surface area (BSA; m2) was calculated 
from rat’s length and weight using the Vallois formula (19), 
and it was used for the index calculations. Stroke volume 
index (SI; mL/beat/m2) and cardiac index (CI; L/min/m2) re-
flect the contractility of the heart and represent the ratios 
FiGure 1. Transthoracic echocardiography (TTe) recordings in a rat with pulmonary arterial hypertension (PaH) obtained by Vivid i 
Cardiovascular ultrasound System equipped with a 10 MHz probe. (A) an image of pulmonary arterial acceleration time (PaaT) and 
(B) an image of tricuspid valve regurgitation (Tr).
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of SV/BSA and CO/BSA, respectively. Thoracic fluid con-
tent index (TFCI; 1/kohm/m2), which represents total tho-
rax conductivity, was computed using the formula (1000/
Zo)/BSA. Velocity index (IC; s-1), also known as myocardial 
contractility index, reflects the peak velocity of blood flow 
in the aorta during systole, and was calculated using the 
formula (dZ/dt)max/Zo ratio. ECG, heart sounds, and ICG sig-
nals were continuously recorded for 60 sec (Figure 3) and 
measurements were performed at the baseline, 4th, and 
7th week.
invasive determination of pulmonary arterial blood 
pressure (PaBPinV)
Invasive pulmonary arterial blood pressure (PABPINV) mea-
surements were performed at the 7th week. Before the 
procedure, rats were intubated with a 16-gauge plastic 
venflon, which was inserted directly into the trachea. Ani-
mals were subsequently attached to a mechanical venti-
lator (Harvard Apparatus 55-7059 inspira ASV ventilator, 
Holliston, MA, USA), ensuring normal breathing. Rats were 
ventilated under a peak pressure of 10 ± 2 cmH2O, a respi-
ratory frequency of 60 ± 5 breath/min, and a FiO2 (fraction 
of inspired oxygen) value of 100%. After this, the mediasti-
num was opened by median sternotomy to locate the pul-
monary artery. PABPINV was measured by a 26-gauge plastic 
venflon that was directly connected to a pressure trans-
ducer (Biopac System Inc.) and signals were continuously 
recorded.
Statistical analysis
Data were tested for normality of distribution with Kol-
mogorov-Smirnov test. Analysis of variance models were 
used to compare the groups at the baseline, 4th, and 7th 
week. Since at the baseline no treatment was applied to 
any group and since at the 4th week the same treatment 
(MCT treatment) was applied to four groups except the 
control, post hoc Dunnett’s test was performed to com-
pare all groups with the control. At the 7th week, all groups 
were compared with each other using one-way analysis of 
variance (ANOVA) followed by Tukey multiple compari-
son test. Data were expressed as mean ± standard devia-
FiGure 2. impedance cardiography (iCG) recordings made 
by eBi100C module using surface electrode pairs (white dots 
1 to 4). an electrical current was applied to the outer sensors 
(white dots 1 and 4) and voltage changes across the thorax 
were detected by the inner electrodes (white dots 2 and 3). 
Three standard electrocardiogram (eCG) electrodes were 
placed in lead i configuration to record eCG signals (black dots 
+, –, G [ground]) and the signals were recorded by an eCG100C 
module. Heart sounds were recorded using Da100C module 
with a physiological microphone (white dot M).
FiGure 3. Simultaneous recordings of impedance cardiog-
raphy (iCG), electrocardiogram (eCG), and heart sounds in a 
rat. (A) Z0 (steady state basal impedance). (B) eCG. Heart rate 
(Hr) was detected by r-r interval detection method in eCG. 
(C) rate of impedance change (dZ/dt). (D) Heart sounds. left 
ventricular ejection time (lVeT) was determined as the dura-
tion of electro-mechanical systole. Thus, lVeT was measured as 
the time interval between the first (S1) and second (S2) heart 
sound using the heart-sounds trigger pulses. (E) Maximum 
rate of impedance change (dZmax/dt).
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tion (SD). The level of statistical significance was set at 0.05. 
Statistical analysis was performed using STATA/MP 11 soft-
ware (Stata Corp LP, College Station, TX, USA).
reSulTS
At the baseline, each group consisted of 14 rats. No rats 
died in the control and PBOS group, and approximate-
ly 3-3.5 weeks after the MCT injection, 4 rats died in PAH 
group, 5 in PSIL group, and 1 in PCOM group. Therefore, at 
the 4th and 7th week, control group had 14, PAH had 10, 
PBOS had 14, PSIL had 9, and PCOM had 13 rats.
Body surface area, systolic arterial blood pressure, and 
mean arterial blood pressure results
No significant differences in BSA (mean ± standard devia-
tion, 0.035 ± 0.0032 m2), SABP (101.70 ± 20.69 mm Hg), and 
MABP (84.41 ± 19.58 mm Hg) were found between the 
groups at any measurement point.
Transthoracic echocardiography results
At the baseline, mean PAAT, TR, and RVSPECHO values 
were similar in all groups (Table 1). At the 4th week, in 
all groups TR and RVSPECHO were significantly higher and 
PAAT was significantly lower than in the control group. 
At the 7th week, RVSPECHO and TR were still significantly 
higher in all groups, except in PSIL group, than in the 
control group. In PSIL group, the values were also signifi-
cantly lower than in PAH, PBOS, and PCOM groups and 
similar to the control group (P < 0.001) (Table 1). PAAT 
values in all groups were lower than in the control group. 
PAAT values in PBOS and PSIL groups were higher than in 
PAH group. Also, PAAT values in PSIL group were higher 
than in PCOM group.
impedance cardiography results
At the baseline and 4th week, there were no significant 
differences in the all ICG parameters between control 
group and other groups (Table 2). At the 7th week, no 
significant differences between the groups were found in 
TFCI, SI, and IC. However, CI was significantly higher in the 
PSIL than in control group. Also, CI in PSIL group had the 
greatest value compared to other groups. HR (which was 
remarkably decreased) was lower in PCOM than in other 
groups, while in PAH it was higher than in other groups. 
However, a significant difference was observed only be-
tween PCOM and PAH.
invasive pulmonary arterial blood pressure (PaBPinV) 
measurements results
PABPinv values in PAH (38.50 ± 19.07 mm Hg) and PBOS 
group (42.00 ± 7.17 mm Hg) were significantly higher 
TaBle 1. Transthoracic echocardiography parameters. The results are expressed as mean ± standard deviation of the mean. One-
way anOVa was used to compare the groups at baseline, 4th, and 7th week. no significant differences in parameters were found 
between the groups at the baseline. in this case, pair wise comparisons were not used*
Parameters Cn PaH PBOS PSil PCOM P
Baseline
PAAT (ms) 25.6 ± 3.0 27.6 ± 1.8 24.8 ± 2.2 25.3 ± 1.7 24.8 ± 2.0 0.053
TR (ms-1) 1.40 ± 0.15 1.27 ± 0.11 1.35 ± 0.10 1.30 ± 0.07 1.33 ± 0.07 0.080
RVSPECHO (mmHg) 9.3 ± 1.5 6.7 ± 0.9 8.1 ± 1.4 6.8 ± 0.6 7.1 ± 0.7 0.054
4th week
PAAT (ms) 25.0 ± 1.6 18.6 ± 2.5† 20.6 ± 2.6† 17.6 ± 1.1† 16.9 ± 1.4† <0.001
TR (ms-1) 1.7 ± 0.08 3.0 ± 0.09† 3.2 ± 0.50† 3.1 ± 0.24† 3.3 ± 0.63† <0.001
RVSPECHO (mmHg) 12.1 ± 0.9 35.7 ± 2.1
† 41.3 ± 14.4† 39.0 ± 5.7† 45.2 ± 18.1† <0.001
7th week
PAAT (ms) 25.7 ± 1.1 14.8 ± 1.1‡ 20.4 ± 1.3‡,§ 22.5 ± 1.8‡,§,¶ 17.9 ± 3.8‡ <0.001
TR (ms-1) 1.6 ± 0.15 3.6 ± 0.4‡ 3.6 ± 0.4‡ 2.3 ± 0.4§,II,¶ 3.6 ± 1.3‡ <0.001
RVSPECHO (mmHg) 10.3 ± 2.2 53.8 ± 11.7
‡ 52.1 ± 12.2‡ 22.3 ± 7.9§,II,¶ 57.9 ± 36.3‡ <0.001
*abbreviations: Cn – control rats treated with saline; PaH – pulmonary arterial hypertension induced rats with monocrotaline; PBOS – PaH rats 
treated with bosentan; PSil – PaH rats treated with sildenafil; PCOM – PaH rats treated with bosentan and sildenafil; PaaT – pulmonary artery ac-
celeration time; Tr – tricuspid valve regurgitation; rVSPeCHO – right ventricular systolic pressure.
†Compared to Cn (4th week).




503Buyukakilli et al: Impedance cardiography in pulmonary arterial hypertension and therapy
www.cmj.hr
than in the control group (18.25 ± 6.14 mm Hg) (P < 0.05). 
No other significant differences in PABPinv were found 
between the groups (PSIL – 32.1 ± 15.6 and PCOM – 
30.9 ± 19.9 mm Hg).
DiSCuSSiOn
Our study found that PAH did not have an effect on LV 
function in rats, while other studies (2,3,8,20,21) attributed 
the changes in cardiac function following administration 
of MCT to pulmonary hypertension.
The ICG is a non-invasive, continuous method with mini-
mal technical requirements and no patient risk. The pul-
satile impedance changes in the ICG directly reflect as-
cending aortic flow and, thus LV function. They are used 
to determine SV, which, when simultaneously measured 
with HR, can be used to calculate CO. In combination with 
heart sounds and ECG signals, ICG provides a continuous 
comprehensive hemodynamic profile for illness/treatment 
evaluations (16,18).
The MCT-induced PAH rat model has been widely used as 
an experimental model of PAH (22) and is the most similar 
animal model to PAH in humans (23). When injected into 
rats in a single subcutaneous or intraperitoneal adminis-
tration, MCT undergoes hepatic transformation by cyto-
chrome P450 monooxygenase in the liver to form MCT 
pyrrole, which causes muscular hypertrophy of the media 
of pulmonary vessels and leads to PAH and RV hypertro-
phy (24).
Our study found no significant difference in non-invasive 
blood pressure measurement value, TTE, and ICG between 
the groups at the baseline. Also, there were no differences 
in BSA, SABP, and MABP between the groups at the 4th and 
the 7th week of the study. Another MCT-induced model of 
PAH (25) showed no changes in mean arterial blood pres-
sure, indicating normal LV function, but found higher RV 
systolic pressure. Indeed, we did not observe a change in 
hemodynamic parameters of LV only in MCT-treated rats. 
So, the impaired cardiac function of rats with PAH may de-
pend only on RV dysfunction. However, Kögler et al (2) re-
ported that the LV may also be involved since neurohor-
monal compensation of depressed cardiac function in PH 
and in certain types of congenital heart diseases affects 
both ventricles.
TaBle 2. impedance cardiographic parameters. The results are expressed as mean ± standard deviation of the mean. One-way 
anOVa was used to compare each parameter between the groups at the baseline, 4th, and 7th week. if no significant differences in 
parameters were found, pair wise comparisons were not used*
Parameters Cn PaH PBOS PSil PCOM P
Baseline
TFCI (L/kohm/m2) 338 ± 159 352 ± 166 274 ± 59 309 ± 65 322 ± 132 0.745
SI (mL/beat/m2) 0.7 ± 0.9 0.5 ± 0.2 0.5 ± 0.2 0.8 ± 0.3 1.2 ± 0.6 0.054
HR (beats/min) 336 ± 67 373 ± 50 337 ± 56 366 ± 42 310 ± 85 0.262
CI (L/min/m2) 0.25 ± 0.35 0.20 ± 0.07 0.17 ± 0.09 0.30 ± 0.09 0.33 ± 0.13 0.310
IC (s-1) 0.06 ± 0.05 0.03 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.06 ± 0.03 0.314
4th week
TFCI (L/kohm/m2) 261 ± 99 288 ± 64 307 ± 91 280 ± 55 295 ± 107 0.816
SI (mL/beat/m2) 0.93 ± 0.29 0.94 ± 0.48 1.14 ± 0.75 1.11 ± 0.62 0.92 ± 0.29 0.822
HR (beats/min) 346 ± 57 371 ± 45 320 ± 43 370 ± 46 366 ± 69 0.145
CI (L/min/m2) 0.31 ± 0.07 0.34 ± 0.16 0.35 ± 0.22 0.41 ± 0.24 0.33 ± 0.08 0.827
IC (s-1) 0.05 ± 0.01 0.04 ± 0.02 0.05 ± 0.03 0.04 ± 0.03 0.03 ± 0.01 0.278
7th week
TFCI (L/kohm/m2) 256 ± 40 320 ± 61 295 ± 114 298 ± 42 301 ± 83 0.413
SI (mL/beat/m2) 0.65 ± 0.38 0.90 ± 0.06 0.89 ± 0.61 1.21 ± 0.71 1.14 ± 0.44 0.099
HR (beats/min) 277 ± 59 367 ± 32 287 ± 65 292 ± 44 261 ± 57‡ 0.044
CI (L/min/m2) 0.17 ± 0.08 0.33 ± 0.03 0.23 ± 0.15 0.34 ± 0.18† 0.29 ± 0.11 0.024
IC (s-1) 0.05 ± 0.01 0.03 ± 0.00 0.05 ± 0.03 0.04 ± 0.02 0.03 ± 0.01 0.193
*abbreviations: Cn – control rats treated with saline; PaH – pulmonary arterial hypertension induced rats with monocrotaline; PBOS – PaH rats 
treated with bosentan; PSil – PaH rats treated with sildenafil; PCOM – PaH rats treated with bosentan and sildenafil; TFCi – thoracic fluid content 
index; Si – stroke volume index; Hr – heart rate; Ci – cardiac index; iC – velocity index.
†Compared to Cn.
‡Compared to PaH.
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In this study, after 4 weeks TR values in PAH, PBOS, PSIL, and 
PCOM groups were significantly higher than in the con-
trol group. An increase in TR and a decrease in PAAT values 
were considered as sufficient evidence that PAH occurred 
in all MCT injected groups. Therefore, 4 weeks after treat-
ment it was concluded that MCT rats had RV hypertension 
and hypertrophy unlike control rats.
On the other hand, TR and RVSPECHO values at the 7th week 
in the PSIL group were similar only to controls. In other 
words, improvement was observed only in PSIL group. 
Choudhary et al (26) reported that bosentan had no ef-
fect on RVSP or mass in normoxic animals. However, in our 
study, sildenafil plus bosentan did not affect RVSPECHO com-
pared to sildenafil alone, which reduced this parameter. 
Such findings should be explained in future studies. Corre-
ia-Pinto et al (27) reported that at the sixth week MCT-treat-
ed rats had lower HR than MCT-treated rats at the fourth 
week, MCT-untreated rats at the fourth week, and MCT-un-
treated rats at the sixth week. Contrary to this, we observed 
that HR of MCT injected groups did not change at the 4th 
week, but that at the 7th week it was higher in PAH group 
and therapy groups, except PCOM group, than in controls. 
However, these increases were not significant. Mean HR in 
PCOM was significantly lower than in PAH group.
Our results indicated that sildenafil treatment deteriorated 
LV cardiac index. Clozel et al (28) showed that 300 mg/kg/d 
bosentan, 100 mg/kg/d sildenafil, or their combination for 
4 weeks was the maximally effective dose in MCT-treated 
rats (28). In our study, bosentan and sildenafil were used in 
such maximally effective doses. Since our findings showed 
that sildenafil treatment deteriorated LV cardiac index, we 
recommend its use in lower doses. However, PABPinv val-
ue in PSIL group was not significantly lower than in PAH 
group. Also, there was a significant difference at the 7th 
week in PABPinv value between PSIL group and controls.
In a similar manner, TR and RVSPECHO values in PSIL group 
were similar to the control group. Clozel et al (28) report-
ed a reduction in right ventricular hypertrophy in all MCT-
induced PAH rat groups treated with bosentan, sildenafil, 
and combination therapy. In our study, PAAT values in the 
groups treated with sildenafil or bosentan increased sig-
nificantly compared to PAH group. Also, although PAAT val-
ues in the combined therapy groups increased compared 
to rats with PAH, this increase was not significant. These 
results demonstrate that PAAT was the best ECHO param-
eter to determine the efficacy of treatment. However, 
it is surprising that after 21 days of treatment both 
sildenafil and bosentan did not lower PABPinv, especially if 
we take into consideration that high doses of agents were 
used. Further studies should clarify such findings.
Echocardiography-based studies carried out in PAH pa-
tients suggested that one of the mechanisms contribut-
ing to LV dysfunction is ventricular interdependence and 
impaired LV filling (29). However, the timing when intrinsic 
LV myocardial dysfunction develops is not completely in-
vestigated.
Benoist et al (13) reported that in rats with MCT-induced 
PAH, electrical remodeling occurred not only in LV but also 
in RV, although in a lesser degree, resulting in increased 
electrical heterogeneity (13). This is not consistent with our 
study. Since rat size, LV function, and blood pressure values 
(BSA, SI, CI, IC, SABP, and MABP) did not differ significantly 
between the 5 groups, it seems that effects of PH are lim-
ited to changes in the RV.
There are a number of limitations of the present study 
that need to be addressed in future research. The first was 
that due to insufficient funding we did not use immuno-
histochemistry analysis. Thus, further studies should de-
termine the ultrastructure of the two ventricles. In addi-
tion, besides the hemodynamic data, LV mass/whole heart 
mass or LV mass/tibial length could provide valuable in-
formation. Also, due to ethical and economic reasons, this 
study was designed to use the minimum number of rats 
necessary. Nevertheless, statistical analysis showed that 
the number of animals used in this study was sufficient to 
analyze the data correctly.
We can conclude that PAH did not have an effect on LV 
function of rats, or if it did, the effect was compensated 
by physiological processes. Our results also indicated that 
sildenafil treatment deteriorated the LV cardiac index.
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